Skip to main content
AI Market Summary
Loading market intelligence...

Reata Pharmaceuticals Inc (RETA) Stock Forecast 2025 - AI Price Prediction & Analysis


Reata Pharmaceuticals Inc (RETA) AI Stock Price Forecast & Investment Analysis

Reata Pharmaceuticals Inc Stock Price Chart and Technical Analysis

Loading Reata Pharmaceuticals Inc interactive price chart and technical analysis...

Reata Pharmaceuticals Inc (RETA) - Comprehensive Stock Analysis & Investment Research

Deep dive into Reata Pharmaceuticals Inc's business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Understanding Company Overview

What this section covers: Essential business information about Reata Pharmaceuticals Inc, including sector classification, industry positioning, and organizational structure.

How to interpret: Company size, sector, and employee count provide context for market position and growth potential. Leadership and founding date indicate stability and experience.

For Reata Pharmaceuticals Inc: Reata Pharmaceuticals Inc operates in the Manufacturing sector, making it an emerging small-cap investment.

Reata Pharmaceuticals Inc (Stock Symbol: RETA) is a leading company in the Manufacturing sector , specifically operating within the Pharmaceutical Preparation Manufacturing industry.

The organization employs approximately 372 professionals worldwide and operates under the strategic leadership of CEO J. Warren Huff.

The company has established itself as an emerging investment opportunity with substantial growth potential.

Understanding Financial Performance

What these metrics mean: Key financial indicators showing Reata Pharmaceuticals Inc's revenue scale, profitability, market value, and shareholder returns.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Reata Pharmaceuticals Inc: With $32M in annual revenue and -270.5% net margin, the company demonstrates developing profitability.

Annual Revenue: $32 million generating a -270.5% net profit margin .

Market Capitalization: $1119 million - Classified as a small-cap investment offering high growth potential.

Return on Equity (ROE): -122.2% - Below-average shareholder return efficiency, indicating areas for operational improvement.

Understanding AI Stock Predictions

What these predictions mean: AI-powered forecasts for Reata Pharmaceuticals Inc stock using machine learning algorithms trained on historical market data and technical indicators.

How to interpret: Positive percentages indicate expected price increases, negative values suggest potential declines. Spearman correlation coefficient shows the statistical relationship between predictions and actual outcomes.

For Reata Pharmaceuticals Inc: Unlock premium access to view detailed AI predictions and price targets.

🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for Reata Pharmaceuticals Inc stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.

Understanding Market Position

What this analysis covers: Reata Pharmaceuticals Inc's competitive positioning, market dynamics, operational efficiency, and strategic advantages within its industry.

How to evaluate: Strong cash flow generation, healthy margins, and market leadership indicate competitive advantages. Growth rates show expansion potential.

For Reata Pharmaceuticals Inc: Market positioning analysis based on available financial and operational metrics.

Reata Pharmaceuticals Inc strategically competes in the highly dynamic Pharmaceutical Preparation Manufacturing marketplace, representing an emerging small-cap investment with substantial growth potential and market disruption capabilities .

The company maintains a healthy 100.0% gross margin, indicating strong pricing power and operational efficiency.

Reata Pharmaceuticals Inc (RETA) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Reata Pharmaceuticals Inc stock analysis.

Loading Reata Pharmaceuticals Inc comprehensive fundamental analysis and insider trading data...

Deep dive into Reata Pharmaceuticals Inc's financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Reata Pharmaceuticals Inc stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Reata Pharmaceuticals Inc: With a P/E ratio of -31.48, the market sees the stock as potentially undervalued.

P/E Ratio -31.48x
P/B Ratio 8.88x
Market Cap $1119M
EPS $-2.20
Book Value/Share $3.50
Revenue/Share $0.31
FCF/Share $-12.97
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Reata Pharmaceuticals Inc converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Reata Pharmaceuticals Inc: An ROE of -122.2% indicates room for improvement in shareholder value creation.

ROE -122.2%
ROA -40.6%
ROIC -64.9%
Gross Margin 100.0%
Operating Margin -143.5%
Net Margin -270.5%
EBT Margin -150.3%
Tax Rate 81.2%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Reata Pharmaceuticals Inc's ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Reata Pharmaceuticals Inc: A current ratio of 12.32 indicates strong liquidity.

Current Ratio 12.32x
Quick Ratio 12.20x
D/E Ratio 1.07x
Financial Leverage 5.32x
Interest Coverage -5.0x
Working Capital $728M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Reata Pharmaceuticals Inc's ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Reata Pharmaceuticals Inc: Free cash flow of $-250M indicates cash challenges that need attention.

Operating Cash Flow $-249M
Free Cash Flow $-250M
Capital Spending $-1M
FCF/Sales -957.2%
CapEx/Sales 12.4%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Reata Pharmaceuticals Inc uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Reata Pharmaceuticals Inc: An asset turnover of 0.02x suggests room for improvement in asset utilization.

Asset Turnover 0.02x
Fixed Assets Turnover 0.2x
Payables Period 9 days
Understanding Financial Statement Data

What these metrics mean: Key figures from Reata Pharmaceuticals Inc's income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Reata Pharmaceuticals Inc: With annual revenue of $32M, Reata Pharmaceuticals Inc represents a smaller but potentially high-growth operation.

Income Statement ($ Millions)
Total Revenue $32M
Operating Income $-254M
Net Income $-87M
R&D Expense $203M
SG&A Expense $900M
Cost of Goods Sold $469M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 79%
Cash & Short-term Investments 78%
Total Liabilities 81%
Short-term Debt 1%
Accounts Receivable 3%
Dividend & Shareholder Information
Shares Outstanding 36M
Growth Metrics (YoY)
EPS Growth -1.3%

Latest Reata Pharmaceuticals Inc Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Reata Pharmaceuticals Inc (RETA) stock price and investment outlook.

, source: Nasdaq

Fintel reports that on June 12, 2023, SVB Leerink upgraded their outlook for Reata Pharmaceuticals Inc - (NASDAQ:RETA) from Market Perform to Outperform. As of June 2, 2023, the average one-year price ...

Reata Pharmaceuticals Inc Competitors & Peer Analysis - Manufacturing Sector

Comparative analysis of Reata Pharmaceuticals Inc against industry peers and competitors in the Manufacturing sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio

Frequently Asked Questions - Reata Pharmaceuticals Inc Stock Forecast

How accurate are Reata Pharmaceuticals Inc stock predictions?

Our AI model shows a 8500% Spearman correlation coefficient for RETA predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Reata Pharmaceuticals Inc stock price forecasts?

Our analysis considers Reata Pharmaceuticals Inc's financial metrics, Manufacturing sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Reata Pharmaceuticals Inc a good investment in 2025?

Based on our AI analysis, Reata Pharmaceuticals Inc shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Reata Pharmaceuticals Inc forecasts updated?

Reata Pharmaceuticals Inc stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want More Advanced Reata Pharmaceuticals Inc Analysis?

Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for Reata Pharmaceuticals Inc stock.

My Portfolio

Investment Dashboard

Loading your portfolio...